BENNETT C FRANK 4

4 · IONIS PHARMACEUTICALS INC · Filed Mar 5, 2026

Insider Transaction Report

Form 4

Period: 2026-03-03

IONIS PHARMACEUTICALS INCIONS

BENNETT C FRANK

EVP, Chief Scientific Officer

Transactions

Exercise/Conversion
Common Stock
2026-03-03$32.60/sh+16,463$536,694→ 117,017 total
Exercise/Conversion
Common Stock
2026-03-03$60.89/sh+48,626$2,960,837→ 165,643 total
Sale
Common Stock
[F1][F2]
2026-03-03$79.10/sh−71,600$5,663,488→ 94,043 total
Sale
Common Stock
[F1][F3]
2026-03-03$79.88/sh−12,687$1,013,410→ 81,356 total
Sale
Common Stock
[F1][F4]
2026-03-03$80.76/sh−802$64,771→ 80,554 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-03-03−16,463→ 2,406 total
Exercise: $32.60From: 2023-01-03Exp: 2032-01-02→ Common Stock (16,463 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-03-03−48,626→ 0 total
Exercise: $60.89From: 2021-01-02Exp: 2027-01-01→ Common Stock (48,626 underlying)

Footnotes (4)

[F1]Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 19, 2025.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.60 to $79.60 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.605 to $80.555 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.61 to $81.07 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.

Signature

By: Patrick R. O'Neil, attorney-in-fact For: C. Frank Bennett|2026-03-05

Documents

1 file

4
edgardoc.xmlPrimary
PRIMARY DOCUMENT